InvestSMART

PharmAust Limited (ASX: PAA) - Announcements

Current share price for PAA : $0.230 0.015 (6.98%)+

ASX company news and announcements for PharmAust Limited (PAA) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All PharmAust Limited (PAA) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than PharmAust Limited (PAA), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for PharmAust Limited (PAA)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
- Dr Kim Agnew appointed Principal Investigator of dog trial 14 May 2021 11:13AM $0.096 $0.230 risen by 139.58%
- Appendix 4C and Quarterly Update 29 Apr 2021 8:18AM $0.098 $0.230 risen by 134.69%
- Phase IIb Canine Trial Identifies Therapeutic Window for MPL 27 Apr 2021 8:30AM $0.095 $0.230 risen by 142.11%
- Epichem OHD Presentation - Waste to Fuels Technology 21 Apr 2021 8:58AM $0.096 $0.230 risen by 139.58%
- PharmAust Receives $750k R&D Tax Incentive Refund 8 Apr 2021 8:25AM $0.105 $0.230 risen by 119.05%
- Leiden Testing Indicates MPL SARS-CoV-2 Antiviral Activity 7 Apr 2021 9:41AM $0.098 $0.230 risen by 134.69%
- Trading Halt 6 Apr 2021 10:38AM $0.098 $0.230 risen by 134.69%
- Pause in Trading 6 Apr 2021 9:48AM $0.098 $0.230 risen by 134.69%
- Update on Phase IIb Clinical Trial of Monepantel in Pet Dogs 30 Mar 2021 9:06AM $0.100 $0.230 risen by 130%
- Epichem business support program for advanced technologies 29 Mar 2021 8:25AM $0.100 $0.230 risen by 130%
- Licensing Agreement to Develop Waste to Fuels Technology 23 Mar 2021 8:49AM $0.100 $0.230 risen by 130%
- Appendix 4D & Half Year Report 26 Feb 2021 2:37PM $0.100 $0.230 risen by 130%
- Update on Phase IIb Clinical Trial recruitment 15 Feb 2021 8:53AM $0.105 $0.230 risen by 119.05%
- Update on COVID-19 testing in the Netherlands 10 Feb 2021 4:20PM $0.110 $0.230 risen by 109.09%
- Virtual Investor Briefing 5 Feb 2021 10:12AM $0.110 $0.230 risen by 109.09%
- Appendix 4C and Quarterly Update 27 Jan 2021 9:16AM $0.105 $0.230 risen by 119.05%
- Epichem Awarded $200K WasteSorted e-Waste Grant 22 Jan 2021 8:17AM $0.098 $0.230 risen by 134.69%
- Leiden University Medical Centre Monepantel COVID-19 Testing 8 Jan 2021 8:20AM $0.110 $0.230 risen by 109.09%
- PAA & ONJCRI to Continue MPL Pre-clinical Investigations 5 Jan 2021 9:58AM $0.110 $0.230 risen by 109.09%
- Appendix 2A & s708 notice 4 Jan 2021 8:16AM $0.105 $0.230 risen by 119.05%
- PAA Commences Manufacture of GMP-Grade MPL for Human Trials 23 Dec 2020 8:21AM $0.105 $0.230 risen by 119.05%
- PharmAust to Commence Phase IIb Dog Cancer Trial 22 Dec 2020 8:15AM $0.105 $0.230 risen by 119.05%
- Epichem Awarded Contract Extension from DNDi 21 Dec 2020 8:18AM $0.110 $0.230 risen by 109.09%
- Appendix 2A & s708 notice (exercise of options) 4 Dec 2020 6:52PM $0.115 $0.230 risen by 100%
- Results of Annual General Meeting 5 Nov 2020 8:22PM $0.110 $0.230 risen by 109.09%

301 - 325 of 796 results

Page 13 of 32

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.